Antiphospholipid syndrome

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 1, 2016, Pages 133-148

  Khamashta, M ^a,b   Taraborelli, M ^c   Sciascia, S ^d   Tincani, A ^e  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b DUBAI HOSPITAL   (United Arab Emirates)

^c SPEDALI CIVILI   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Pregnancy; Thrombosis; 2 glycoprotein I

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BIOLOGICAL MARKER; DABIGATRAN ETEXILATE; EDOXABAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NEW DRUG; PROTHROMBIN ANTIBODY; RIVAROXABAN; PHOSPHOLIPID ANTIBODY;

ALTERNATIVE MEDICINE; ANTIPHOSPHOLIPID SYNDROME; DISEASE ASSOCIATION; HUMAN; NONHUMAN; PATHOGENESIS; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; THROMBOSIS PREVENTION; FEMALE; IMMUNOLOGY; PREGNANCY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 84964813614     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.04.002     Document Type: Review

References (108)

1. *[1] Miyakis, S., Lockshin, M.D., Atsumi, T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
2. [2] Merashli, M., Noureldine, M.H., Uthman, I., et al. Antiphospholipid syndrome: an update. Eur J Clin Investig 45 (2015), 653–662.
3. [3] Canaud, G., Bienaime, F., Tabarin, F., et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 371 (2014), 303–312.
4. [4] Canaud, G., Terzi, F., Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 371 (2014), 1554–1555.
5. [5] Galli, M., Luciani, D., Bertolini, G., et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003), 1827–1832.
6. [6] Forastiero, R., Martinuzzo, M., Pombo, G., et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 3 (2005), 1231–1238.
7. [7] Pengo, V., Ruffatti, A., Legnani, C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8 (2010), 237–242.
8. [8] Sciascia, S., Sanna, G., Murru, V., et al. GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 52 (2013), 1397–1403.
9. [9] Galli, M., Luciani, D., Bertolini, G., et al. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102 (2003), 2717–2723.
10. [10] Urbanus, R.T., Siegerink, B., Roest, M., et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 8 (2009), 998–1005.
11. [11] Tektonidou, M.G., Laskari, K., Panagiotakos, D.B., et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61 (2009), 29–36.
12. *[12] Sciascia, S., Murru, V., Sanna, G., et al. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 10 (2012), 2512–2518.
13. [13] Giannakopoulos, B., Passam, F., Ioannou, Y., et al. How we diagnose the antiphospholipid syndrome. Blood 113 (2009), 985–994.
14. [14] Kenet, G., Aronis, S., Berkun, Y., et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 37 (2011), 802–809.
15. [15] Garcia, D., Akl, E.A., Carr, R., et al. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122 (2013), 817–824.
16. [16] Bertolaccini, M.L., Amengual, O., Atsumi, T., et al. ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA. Lupus 2011:20 (April 2010), 191–205.
17. [17] Meijide, H., Sciascia, S., Sanna, G., et al. The clinical relevance of IgA anticardiolipin and IgA anti-beta2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 12 (2013), 421–425.
18. [18] Murthy, V., Willis, R., Romay-Penabad, Z., et al. Value of isolated IgA anti-beta2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65 (2013), 3186–3193.
19. [19] Andreoli, L., Fredi, M., Nalli, C., et al. Clinical significance of IgA anti-cardiolipin and IgA anti-beta2glycoprotein I antibodies. Curr Rheumatol Rep, 15, 2013, 343.
20. [20] Bertolaccini, M.L., Atsumi, T., Koike, T., et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 93 (2005), 289–297.
21. [21] Pengo, V., Denas, G., Bison, E., et al. Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thromb Res 126 (2010), 150–153.
22. [22] Bertolaccini, M.L., Atsumi, T., Khamashta, M.A., et al. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 25 (1998), 1104–1108.
23. [23] Sciascia, S., Sanna, G., Murru, V., et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost, 2013, 111.
24. [24] George, J., Gilburd, B., Hojnik, M., et al. Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding. J Immunol 160 (1998), 3917–3923.
25. [25] Yang, C.D., Chen, S.L., Shen, N., et al. Detection of anti-recombinant beta 2-glycoprotein 1 and anti-recombinant beta 2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol Int 18 (1998), 5–10.
26. *[26] Andreoli, L., Chighizola, C.B., Nalli, C., et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 67 (2015), 2196–2204.
27. [27] de Laat, B., de Groot, P.G., Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 13 (2011), 70–76.
28. [28] de Laat, B., Pengo, V., Pabinger, I., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7 (2009), 1767–1773.
29. [29] Banzato, A., Pozzi, N., Frasson, R., et al. Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res 128 (2011), 583–586.
30. [30] Erkan, D., Yazici, Y., Peterson, M.G., et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41 (2002), 924–929.
31. [31] Matyja-Bednarczyk, A., Swadzba, J., Iwaniec, T., et al. Risk factors for arterial thrombosis in antiphospholipid syndrome. Thromb Res 133 (2014), 173–176.
32. [32] Esdaile, J.M., Abrahamowicz, M., Grodzicky, T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 (2001), 2331–2337.
33. *[33] Kaiser, R., Cleveland, C.M., Criswell, L.A., Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68 (2009), 238–241.
34. [34] Lefevre, G., Lambert, M., Bacri, J.L., et al. Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. Lupus 20 (2011), 861–865.
35. [35] Gris, J.C., Bouvier, S., Molinari, N., et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 119 (2012), 2624–2632.
36. [36] Martinez-Zamora, M.A., Peralta, S., Creus, M., et al. Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. Ann Rheum Dis 71 (2012), 61–66.
37. [37] Andreoli, L., Tincani, A., Beyond the “syndrome”: antiphospholipid antibodies as risk factors. Arthritis Rheum 64 (2012), 342–345.
38. [38] Otomo, K., Atsumi, T., Amengual, O., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64 (2012), 504–512.
39. [39] Sciascia, S., Cosseddu, D., Montaruli, B., et al. Risk Scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 70 (2011), 1517–1518.
40. [40] Sciascia, S., Cuadrado, M.J., Sanna, G., et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res Hob 66 (2014), 1915–1920.
41. [41] Sciascia, S., Sanna, G., Murru, V., et al. The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford) 54 (2015), 134–138.
42. [42] Zuily, S., de Laat, B., Mohamed, S., et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 54 (2015), 2071–2075.
43. *[43] Erkan, D., Aguiar, C.L., Andrade, D., et al. 14th International Congress on antiphospholipid antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13 (2014), 685–696.
44. [44] Ginsburg, K.S., Liang, M.H., Newcomer, L., et al. Anticardiolipin antibodies and the risk for Ischemic stroke and venous thrombosis. Ann Intern Med 117 (1992), 997–1002.
45. [45] Becattini, C., Agnelli, G., Schenone, A., et al. Aspirin for preventing the recurrence of venous thromboembolism. N. Engl J Med 366 (2012), 1959–1967.
46. [46] Cuadrado, M.J., Bertolaccini, M.L., Seed, P.T., et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) 53 (2014), 275–284.
47. [47] Kearon, C., Ginsberg, J.S., Kovacs, M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349 (2003), 631–639.
48. [48] Finazzi, G., Marchioli, R., Brancaccio, V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 (2005), 848–853.
49. [49] Pengo, V., Ruiz-Irastorza, G., Denas, G., et al. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’. Autoimmun Rev 11 (2012), 577–580.
50. [50] Levine, S.R., Brey, R.L., Tilley, B.C., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, 291, 2004 576–584.
51. *[51] Ruiz-Irastorza, G., Hunt, B.J., Khamashta, M.A., A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 57 (2007), 1487–1495.
52. [52] Ruiz-Irastorza, G., Khamashta, M.A., Hunt, B.J., et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Archives Intern Med 162 (2002), 1164–1169.
53. [53] Sciascia, S., Lopez-Pedrera, C., Cecchi, I., et al. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology (Oxford), 2016 Feb 3 pii: kev445. [Epub ahead of print].
54. [54] Sciascia, S., Khamashta, M.A., D'Cruz, D.P., Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol 26 (2014), 269–275.
55. [55] Erkan, D., Vega, J., Ramon, G., et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 65 (2013), 464–471.
56. [56] Bakimer, R., Fishman, P., Blank, M., et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Investig 89 (1992), 1558–1563.
57. [57] Rand, J.H., Wu, X.X., Quinn, A.S., et al. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 19 (2010), 460–469.
58. [58] Salafia, C.M., Cowchock, F.S., Placental pathology and antiphospholipid antibodies: a descriptive study. Am J Perinatol 14 (1997), 435–441.
59. [59] Tong, M., Viall, C.A., Chamley, L.W., Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum Reprod Update 21 (2015), 97–118.
60. [60] Di Simone, N., Meroni, P.L., de Papa, N., et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 43 (2000), 140–150.
61. [61] Viall, C.A., Chen, Q., Liu, B., et al. Antiphospholipid antibodies internalised by human syncytiotrophoblast cause aberrant cell death and the release of necrotic trophoblast debris. J Autoimmun 47 (2013), 45–47.
62. Meroni, P.L., Borghi, M.O., Raschi, E., et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7 (2011), 330–339.
63. [63] Müller-Calleja, N., Köhler, A., Siebald, B., et al. Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. Thromb Haemost 113 (2015), 1071–1083.
64. [64] Ulrich, V., Gelber, S.E., Vukelic, M., et al. ApoE Receptor 2 mediates trophoblast dysfunction and pregnancy complications induced by antiphospholipid antibodies in mice. Arthritis Rheumatol 68 (2016), 730–739.
65. [65] Poulton, K., Ripoll, V.M., Pericleous, C., et al. Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. Am J Reprod Immunol 73 (2015), 390–401.
66. Ramires de Jesus, G., Agmon-Levin, N., Andrade, C.A., et al. 14th International congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Autoimmun Rev 13 (2014), 795–813.
67. [67] Abou-Nassar, K., Carrier, M., Ramsay, T., et al. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 128 (2011), 77–85.
68. [68] Silver, R.M., Parker, C.B., Reddy, U.M., et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol 122 (2013), 641–657.
69. [69] Chighizola, C.B., Andreoli, L., Ramires de Jesus, G., et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus 24 (2015), 980–984.
70. [70] Erkan, D., Lockshin, M.D., APS ACTION members. APS ACTION-AntiPhospholipid syndrome Alliance for clinical trials and InternatiOnal networking. Lupus 21 (2012), 695–698.
71. [71] Ulcova-Gallova, Z., Krauz, V., Novakova, P., et al. Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Am J Reprod Immunol 54 (2005), 112–117.
72. [72] Žigon, P., Perdan Pirkmajer, K., Tomšič, M., et al. Anti-Phosphatidylserine/Prothrombin antibodies are associated with adverse pregnancy outcomes. J Immunol Res, 2015, 2015, 975704.
73. [73] Sater, M.S., Finan, R.R., Abu-Hijleh, F.M., et al. Anti-phosphatidylserine, anti-cardiolipin, anti-β2 glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestational weeks. Eur J Obstet Gynecol Reprod Biol 163 (2012), 170–174.
74. [74] Bertolaccini, M.L., Amengual, O., Andreoli, L., et al. 14th International congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13 (2014), 917–930.
75. [75] Simchen, M.J., Dulitzki, M., Rofe, G., et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 90 (2011), 1428–1433.
76. [76] Boffa, M.C., Boinot, C., De Carolis, S., et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Haemost 102 (2009), 25–28.
77. [77] Gardiner, C., Hills, J., Machin, S.J., et al. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 22 (2013), 18–25.
78. [78] Ofer-Shiber, S., Molad, Y., Frequency of vascular and pregnancy morbidity in patients with low vs. moderate-to-high titers of antiphospholipid antibodies. Blood Coagul Fibrinolysis 26 (2015), 261–266.
79. [79] Lockshin, M.D., Kim, M., Laskin, C.A., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 64 (2012), 2311–2318.
80. Alijotas-Reig, J., Ferrer-Oliveras, R., Ruffatti, A., et al. The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 14 (2015), 387–395.
81. [81] Fredi, M., Aggogeri, E., Bettiga, E., et al. A multicenter evaluation of obstetric and maternal outcome in prospectively followed pregnant patients with confirmed positivity for antiphospholipid antibodies (apl) [abstract]. Arthritis Rheumatol, 67(Suppl. 10), 2015.
82. [82] Kim, M.Y., Buyon, J.P., Guerra, M.M., et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 214 (2016), 108.e1–108.e14.
83. [83] Cnossen, J.S., Morris, R.K., ter Riet, G., et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 178 (2008), 701–711.
84. [84] Velauthar, L., Plana, M.N., Kalidindi, M., et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. Ultrasound Obstet Gynecol 43 (2014), 500–507.
85. [85] Girardi, G., MRI-based methods to detect placental and fetal brain abnormalities in utero. J Reprod Immunol 114 (2016), 86–91.
86. Bates, S.M., Greer, I.A., Middeldorp, S., et al. American college of chest physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141 (2012), e691S–736S.
87. [87] Empson, M., Lassere, M., Craig, J., et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev, 18, 2005 CD002859.
88. [88] Mak, A., Cheung, M.W., Cheak, A.A., et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 49 (2010), 281–288.
89. [89] Ziakas, P.D., Pavlou, M., Voulgarelis, M., Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 115 (2010), 1256–12562.
90. [90] Fishman, P., Falach-Vaknin, E., Sredni, B., et al. Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am J Reprod Immunol 35 (1996), 80–84.
91. [91] Mastrolia, S.A., Mazor, M., Holcberg, G., et al. The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications. Thromb Haemost 113 (2015), 1236–1246.
92. [92] Gómez-Puerta, J.A., Cervera, R., Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome?. Lupus 22 (2013), 754–755.
93. [93] Wu, X.X., Guller, S., Rand, J.H., Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol, 205, 2011 576–514.
94. [94] Siascia, S., Hunt, B.J., Talaver-Garcia, E., et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 214 (2016), 273.e1–273.e8.
95. [95] De Carolis, S., Botta, A., Salvi, S., et al. Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment. Autoimmun Rev 14 (2015), 760–762.
96. [96] Sneiderman, C., Wilson, J., Effects of corticosteroids on complement and the neutrophilic polymorphonuclear leukocyte. Transpl Proc 7 (1975), 41–48.
97. [97] Bramham, K., Thomas, M., Nelson-Piercy, C., et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 117 (2011), 6948–6951.
98. [98] Ruffatti, A., Marson, P., pengo, V., et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A case report of 9 cases and a review of the literature. Autoimmun Rev 6 (2007), 196–202.
99. [99] Bortolati, M., Marson, P., Chairelli, S., et al. Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther Apher Dial 13 (2009), 157–160.
100. [100] Ruffatti, A., Favaro, M., Brucato, A., et al. Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block. Transfus Apher Sci 53 (2015), 269–278.
101. [101] Yu, Z., Lennon, V.A., Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340 (1993), 227–228.
102. [102] Dendrinos, S., Sakkas, E., Makrakis, E., Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 104 (2009), 223–225.
103. [103] Empson, M., Lassere, M., Craig, J., et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev, 2, 2005 CD002859.
104. [104] Arachchillage, D.R.J., Machin, S.J., Mackie, I.J., et al. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost 113 (2015), 13–19.
105. [105] Amengual, O., Fujita, D., Carmona, L., et al. Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. Lupus 24 (2015), 1135–1142.
106. [106] De la Torre, Y.M., Pregnolato, F., D'Amelio, F., et al. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J Autoimmun 38 (2012), J209–J215.
107. [107] Agostinis, C., Durigutto, P., Sblattero, D., et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 123 (2014), 3478–3487.
108. [108] Cervera, R., Serrano, R., Pons-Estel, G.J., et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis, 74, 2015 1011–1008.